20 categories
Pharmacology
Receptor biology, pharmacokinetics and formulation chemistry — the mechanistic layer under everything else.
50 topics · page 1 of 2
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+6 | 10 | 34k | 20d |
|
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 32k | 8mo | |
|
About the Formulation chemistry category
Buffers, pH, isotonicity, preservatives, lyophilisation and excipient function. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and…
|
4 | 4.5k | 18mo | |
|
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Glucagon receptor agonism: setting out the arithmetic in full, because I have had to do…
|
2 | 5.1k | 20mo | |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
|
+52 | 57 | 25k | just now |
|
Coming back to: Solubility limits and what a cloudy solution is telling you
On the subject in the title: Solubility limits and what a cloudy solution is telling you Working notes rather than a conclusion. Reading back through what has been written here about Solubility limits, three…
|
+38 | 43 | 29k | 13h |
|
GIP receptor agonism and the argument about direction — does this still hold?
GIP receptor agonism and the argument about direction — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about GIP receptor agonism…
|
+10 | 14 | 15k | 16h |
|
Solubility limits and what a cloudy solution is telling you
Solubility limits and what a cloudy solution is telling you — setting out what I have, and where I think it stops being reliable. The question about solubility limits that I actually want answered is the…
|
+11 | 15 | 34k | 20h |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
|
+90 | 98 | 30k | 22h |
|
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Peak-to-trough ratio,…
|
+57 | 61 | 708 | 1d |
|
Coming back to: Time to steady state after a dose increase
Time to steady state after a dose increase Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I think the…
|
+104 | 110 | 16k | 2d |
|
Preservatives: function, testing, and limits — one year on
On the subject in the title: Preservatives: function, testing, and limits — one year on Working notes rather than a conclusion. Asking about Preservatives directly, because I have read four threads on it and…
|
+28 | 32 | 437 | 8d |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+58 | 64 | 9.7k | 2mo |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of clearance pathways is wrong? I…
|
+11 | 15 | 43k | 2mo |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
|
+73 | 78 | 3.5k | 2mo |
|
Coming back to: Washout: how long is long enough, and for what purpose
Posting this under the heading it deserves: Washout: how long is long enough, and for what purpose Everything below is what sits behind that. A narrow question about Washout, deliberately narrow, because the…
|
+128 | 139 | 3k | 3mo |
|
Follow-up: Lyophilisation and why the cake looks the way it does
Lyophilisation and why the cake looks the way it does Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about Lyophilisation in a thread last spring and I would…
|
+10 | 14 | 11k | 3mo |
|
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
|
+7 | 11 | 43k | 3mo |
|
[2026 update] Buffers, pH and why a formulation is a formulation
Posting this under the heading it deserves: Buffers, pH and why a formulation is a formulation Everything below is what sits behind that. A formulation question rather than a pharmacological one, though the…
|
2 | 773 | 3mo | |
|
Coming back to: Half-life, steady state, and accumulation worked through
On the subject in the title: Half-life, steady state, and accumulation worked through Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+14 | 18 | 15k | 3mo |
|
Half-life, steady state, and accumulation worked through — a second dataset
Half-life, steady state, and accumulation worked through — a second dataset — setting out what I have, and where I think it stops being reliable. Working through the kinetics rather than the pharmacology,…
|
+110 | 126 | 14k | 4mo |
|
Adsorption to container surfaces and to plastics
On the subject in the title: Adsorption to container surfaces and to plastics Working notes rather than a conclusion. I was wrong about adsorption in a thread last spring and I would like to correct it…
|
+13 | 17 | 4.3k | 5mo |
|
Lyophilisation and why the cake looks the way it does
Posting this under the heading it deserves: Lyophilisation and why the cake looks the way it does Everything below is what sits behind that. I was wrong about lyophilisation in a thread last spring and I…
|
+33 | 37 | 60k | 6mo |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…
|
+57 | 63 | 1k | 6mo |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Glucagon receptor agonism that I did not know…
|
+5 | 9 | 21k | 7mo |
|
Revisiting: GLP-1 receptor distribution: central and peripheral
Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
|
+61 | 66 | 15k | 8mo |
|
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A follow-up question about appetite effects that I did not know to ask the first time. The earlier thread…
|
+86 | 90 | 61k | 9mo |
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and satiety directly, because I have read four…
|
+22 | 26 | 1.8k | 9mo |
|
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. A follow-up question about Subcutaneous absorption kinetics and site that I did not…
|
4 | 9.9k | 10mo | |
|
Washout: how long is long enough, and for what purpose
Washout: how long is long enough, and for what purpose — setting out what I have, and where I think it stops being reliable. A narrow question about washout, deliberately narrow, because the broad version has…
|
+63 | 70 | 13k | 10mo |